Moreover, the loss of ERβ is associated with enhanced CRC proliferation potential [121], leading to the hypothesis that high ERβ expression may not only be protective against developing CRC but also a prognostic marker and molecular target in the treatment of colon cancer [122,123]. Here, ESR2 is linked to colorectal carcinoma.